Press Release: Exact Sciences Schedules Second Quarter 2025 Earnings Call

Dow Jones
2025/07/14
MADISON, Wis.--(BUSINESS WIRE)--July 14, 2025-- 

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Second quarter 2025 webcast & conference call details

 
Date:         Wednesday, August 6, 2025 
Time:         5 p.m. ET 
Webcast:      The live webcast can be accessed at www.exactsciences.com 
Telephone:    Domestic callers, dial 888-330-2384 International callers, dial 
              +1 240-789-2701 Access code for both domestic and international 
              callers: 4437608 
 

A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard$(R)$ and Oncotype DX(R) , along with innovative solutions like Oncodetect$(TM)$ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow @ExactSciences on X, or connect on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250714856984/en/

 
    CONTACT:    Investor Contact: 

Derek Leckow

608-893-0009

investorrelations@exactsciences.com

 
 

(END) Dow Jones Newswires

July 14, 2025 06:07 ET (10:07 GMT)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10